Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | -0.60 | 0.02 | 0.01 |
| FCF Yield | 23.68% | -19.97% | -30.24% | -34.09% |
| EV / EBITDA | 20.85 | 29.12 | -7.47 | -3.44 |
| Quality | ||||
| ROIC | 6.47% | 6.51% | -30.97% | -29.46% |
| Gross Margin | 94.74% | 97.32% | 87.70% | -81.69% |
| Cash Conversion Ratio | -35.35 | -49.24 | 1.30 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 112.69% | 19.55% | -5.98% | -5.73% |
| Free Cash Flow Growth | 196.43% | 20.77% | 21.08% | -87.36% |
| Safety | ||||
| Net Debt / EBITDA | -4.29 | 9.27 | -1.75 | 0.03 |
| Interest Coverage | -0.78 | 0.71 | -3.69 | -4.86 |
| Efficiency | ||||
| Inventory Turnover | 0.33 | 0.13 | 0.17 | 0.25 |
| Cash Conversion Cycle | 131.81 | 176.29 | 364.11 | 101.79 |